[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360; 381-400; 401-420; 421-440; 461-480; 481-500


NICE TAs 441-460



DHFT Formulary link 

East Midlands Cancer Network link (cancer drugs only) 

TA 441

Daclizumab for treating relapsing-remitting multiple sclerosis

TA 442

Ixekizumab for treating moderate to severe plaque psoriasis 

13.5.3 Drugs affecting the immune response

TA 443 

Obeticholic acid for treating primary biliary cholangitis 

Via Regional MDT (Nottingham)

TA 444 

Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) 

Not recommended by NICE

TA 445

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout 


TA 446

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma


Link to cancer network protocol

TA 447

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer


Link to cancer network protocol

TA 448

Etelcalcetide for treating secondary hyperparathyroidism Hypercalcemia and Hypercalciuria

TA 449

Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease


Link to cancer network protocol

TA 450

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia


Pts treated at transplant centre

TA 451

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia


Link to cancer network protocol

TA 452

Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)

Not recommended by NICE

TA 453

Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)

Not recommended by NICE

TA 454

Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)

Not recommended by NICE

TA 455

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

TA 456

Ustekinumab for moderately to severely active Crohn’s disease after previous treatment

1.5 Treatment of chronic diarrhoeas

TA 457

Carfilzomib for previously treated multiple myeloma


Link to cancer network protocol

TA 458

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane


Link to cancer network protocol

TA 459

Collagenase clostridium histolyticum for treating Dupuytren's contracture

TA 460

Adalimumab and dexamethasone for treating non-infectious uveitis